Yatharth Hospital & Trauma Care Services Ltd

- The company currently has a strong cash position of close to INR 200 crores as of December 31, 2025. - They can also avail certain debt if needed for acquisitions or expansion. - Internal accruals are strong, enabling the company to fund capital expenditure for the next 3 years. - Fund deployment of INR 1,500 crores capex for reaching 5,000 beds will be spread over 5 years. - Acquisitions are planned over the coming years and will be funded through a mix of cash, debt, and internal accruals. - No specific mention of an immediate upcoming fundraising through equity or debt, but plans include leveraging various funding sources as required.

- Yatharth Hospitals plans a total capex of around INR 1,500 crores over the next 4-5 years. - The capex aims to add close to 5,000 beds within the next 3-3.5 years. - Expansion will be a mix of greenfield, brownfield, and asset-light models, with capex per bed around INR 60 lakhs on average. - Specific greenfield and brownfield additions include 500 brownfield beds in Noida and Noida Extension. - The company targets major growth in the NCR region and other large cities in North India. - Current cash and bank balance is close to INR 200 crores, with plans to use internal accruals and debt for future acquisitions and expansions. - New hospitals in Faridabad and Delhi have higher capex per bed, around INR 80-90 lakhs. - Acquisitions will continue over the coming years as part of growth strategy.

- Company targets reaching close to 5,000 beds in the next 3-4 years with a mix of greenfield, brownfield, and asset-light expansions, mainly in NCR and major North Indian cities. - Q4 FY '26 expected to perform better than Q3 with improved EBITDA margins targeting 24-25% consolidated level in FY '27. - Existing hospitals showing strong growth; Q3 FY '26 revenue up 46% YoY and 15% QoQ, driven by existing hospitals growing 33% YoY. - New hospitals (New Delhi, Faridabad Sector-20) ramping up occupancy with expected breakeven within 12-15 months. - Oncology business expected to grow from 10% to around 15% of specialty revenue within 1.5 years, supporting ARPOB and revenue growth. - ARPOB growing at over 10% YoY with Noida Extension achieving INR44,000 ARPOB, indicating pricing strength and volume growth. - Medical tourism showing incremental growth potential contributing to revenue expansion.

- Targeting blended EBITDA margin of 24%-25% on a consolidated level for FY '27 amid growth phase (Page 19). - New hospitals (Delhi Model Town, Faridabad Sector-20) expected to reach operational breakeven within 12-15 months, reducing losses and improving margins (Page 18). - EBITDA margin without new hospitals approximately 28%-29%; new hospital additions cause temporary EBITDA drag (Page 17). - ARPOB expected to grow ~10% year-on-year in coming periods, supporting revenue and margin expansion (Page 17). - Revenue growth driven by existing hospitals at 33% YoY; Q3 FY26 revenues at INR3,205 million, up 46% YoY (Page 5). - Net profit after tax up 41% YoY; adjusted PAT up 80% YoY (Page 5). - Capex of INR1,500 crores planned over 5 years to increase bed capacity to 5,000, supporting scalable growth (Pages 19 & 14). Overall, consistent growth in operating earnings and profits is expected, with margin improvement as new hospitals mature.

- Yatharth Hospitals is targeting to reach close to 5,000 beds in the next 3 years through announced deals. - Deployment of these beds will be spread over 4 to 5 years with a mix of greenfield, brownfield, and asset-light expansions. - Combined planned capex for this expansion is around INR 1,500 crores, implying approximately INR 60 lakhs per bed. - Focus geography for expansion is primarily NCR, followed by major cities in North India. - The expansion includes around 2,000 incremental beds with capex of INR 1,500 crores, in addition to 500 beds brownfield expansions already planned at Noida and Noida Extension. - Fund deployment for this capex is planned over 5 years.